20 JUNE at 17h45
|
SYMPOSIUM – Room MIZAR
OPTIMIZING ADJUVANT ENDOCRINE THERAPIES: THE USE OF AROMATASE INHIBITORS
Chair: A. Goldhirsch
"The best endpoint: looking at relapse, quality of life and economics"
A. Coates
"Letrozole as part of adjuvant strategy: new data"
C. Tondini
"The best way to predict endocrine responsiveness: the case of Letrozole"
G. Viale
Supported by Novartis |
| 20 JUNE at 18h45 |
SYMPOSIUM – Room MIZAR
IMPROVING SUPPORT FOR PATIENTS WITH BREAST CANCER TREATED WITH CYTOTOXICS
Chair: E. Bajetta – F. Nolé
“Antiemetics”
V. Lorusso
“Reducing toxicity of CT”
H. Rugo
Supported by Italfarmaco |
21 JUNE at 10h35
|
COFFEE WITH THE EXPERT – ROOM ANDROMEDA
INTERFERING WITH ANGIOGENESIS USING ORAL CYTOTOXICS. EFFICACY OF METRONOMIC TREATMENTS: HOW TO IMPROVE AND HOW TO MEASURE?
Chair: S. Cinieri
Speaker: F. Nolé
Supported by Pierre Fabre Pharma |
| 21 JUNE at 12h45 |
SYMPOSIUM – Room QUASAR
TRASTUZUMAB IN THE ADJUVANT SETTING: OPEN QUESTIONS
Chair: A. Goldhirsch
“Using adjuvant trastuzumab: sequential Vs. combination”
L. Biganzoli
“Using adjuvant trastuzumab: Are issues of duration of treatment or combination with radiation therapy settled?”
M. De Laurentiis
Supported by Roche |
| 21 JUNE at 16h20 |
COFFEE WITH THE EXPERT – ROOM ANDROMEDA
IMPROVING THE QUALITY OF LIFE OF YOUNG WOMEN WITH ENDOCRINE THERAPY
Chair: F. Peccatori
Speaker: P. Sismondi
Supported by Ipsen |
| 21 JUNE at 18h15 |
SYMPOSIUM – ROOM MIZAR
ENDOCRINE TREATMENT OF BREAST CANCER: CURRENT DEVELOPMENT
Chair: D. Amadori
“Anastrozole: ten years of trials and clinical practice”
P. Marchetti
“Long term tolerance of aromatase inhibitors”
L. Biganzoli
“Fulvestrant: an alternative choice for women with advanced breast cancer”
F. Montemurro
supported by Astrazeneca |
| 21 JUNE at 19h15 |
COCKTAIL WITH THE EXPERT – ROOM MIZAR
IMPROVING THE APPROACH TO HER2 POSITIVE DISEASE
Chair: A. Di Leo
“Mechanisms of resistence of anti HER2 agents”
A. Di Leo
“Future directions in management of HER2 positive breast cancer”
P. Pronzato
Supported by GlaxoSmithKline |
| 22 JUNE at 07h15 |
BREAKFAST WITH THE EXPERT – ROOM VESTA
TAXANES IN EARLY BREAST CANCER
Chair: S. Cinieri
Speaker: V. Lorusso
supported by Sanofi Avenis |
| 22 JUNE at 10h30 |
COFFEE WITH THE EXPERT – ROOM ANDROMEDA
ANTHRACYCLINES AND HERCEPTIN: AN EFFECTIVE AND SAFE COMBINATION
Chair: P. Pronzato
Speaker: V. Lorusso
supported by Cephalon |
| 22 JUNE at 12h20 |
SYMPOSIUM – ROOM QUASAR
BEVACIZUMAB FOR BREAST CANCER: IS IT READY FOR PRIME TIME?
Chair: S. Cinieri
“Antiangiogenetics in breast cancer background”
F. Bertolini
“Optimizing bevacizumab therapy in breast cancer”
M. Colleoni
Supported by Roche |
| 23 JUNE at 16h00 |
COFFEE WITH THE EXPERT – ROOM ANDROMEDA
SWITCHING TO EXEMESTANE IMPROVES O.S.?: IES, STUDY RESULTS
Chair: S. Cinieri
Speaker: M. De Laurentiis
Supported by Pfizer |
HOME PAGE
Wed, 20 june 2007